We describe a favourably response to LEV in two Juvenile Myoclonic Epilepsy (JME)-patients who were resistant to first line therapy (VPA, LTG or AZM). In both patients, VPA (1.5-1.7g/day) failed to control seizures and induced weight gain in one. Shifting VPA to LTG (400 mg/day) provoked a paradoxical increase of myoclonic jerks in both patients. Montherapy with AZM (500 mg/die) was uneffective too. Monotherapy with LEV (2000 mg/die) induced a prompt and durable (24 months) response in both patients. Monotherapy with LEV is effective and well tolerated in JME-patients with resistance or intolerance to conventional AED.
Effectiveness of Levetiracetam in JME-patients with resistance or intolerance to conventional AED
Aguglia U
2004-01-01
Abstract
We describe a favourably response to LEV in two Juvenile Myoclonic Epilepsy (JME)-patients who were resistant to first line therapy (VPA, LTG or AZM). In both patients, VPA (1.5-1.7g/day) failed to control seizures and induced weight gain in one. Shifting VPA to LTG (400 mg/day) provoked a paradoxical increase of myoclonic jerks in both patients. Montherapy with AZM (500 mg/die) was uneffective too. Monotherapy with LEV (2000 mg/die) induced a prompt and durable (24 months) response in both patients. Monotherapy with LEV is effective and well tolerated in JME-patients with resistance or intolerance to conventional AED.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
